Target Price | $254.56 |
Price | $173.79 |
Potential | 46.47% |
Number of Estimates | 27 |
27 Analysts have issued a price target Biogen 2025 . The average Biogen target price is $254.56. This is 46.47% higher than the current stock price. The highest price target is $342.00 96.79% , the lowest is $180.00 3.57% . | |
A rating was issued by 37 analysts: 24 Analysts recommend Biogen to buy, 13 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2025 of 46.47% . Most analysts recommend the Biogen stock at Purchase. |
29 Analysts have issued a sales forecast Biogen 2024 . The average Biogen sales estimate is $9.6b . This is 4.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.7b 5.60% , the lowest is $9.5b 2.49% .
This results in the following potential growth metrics:
2023 | $9.4b | 0.17% |
---|---|---|
2024 | $9.6b | 2.29% |
2025 | $9.5b | 0.92% |
2026 | $9.7b | 1.73% |
2027 | $10.0b | 2.83% |
2028 | $10.1b | 1.26% |
9 Analysts have issued an Biogen EBITDA forecast 2024. The average Biogen EBITDA estimate is $3.4b . This is 23.42% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 43.63% , the lowest is $3.0b 7.46% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $2.1b | 23.87% |
---|---|---|
2024 | $3.4b | 59.53% |
2025 | $3.6b | 5.92% |
2026 | $3.7b | 2.31% |
2027 | $4.3b | 16.39% |
2028 | $4.9b | 15.37% |
2023 | 22.58% | 23.74% |
---|---|---|
2024 | 35.21% | 55.95% |
2025 | 37.64% | 6.90% |
2026 | 37.86% | 0.58% |
2027 | 42.85% | 13.18% |
2028 | 48.82% | 13.93% |
12 Biogen Analysts have issued a net profit forecast 2024. The average Biogen net profit estimate is $1.8b . This is 9.96% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.1b 30.08% , the lowest is $1.6b 2.53% .
This results in the following potential growth metrics and future Net Margins:
2023 | $1.2b | 61.81% |
---|---|---|
2024 | $1.8b | 52.72% |
2025 | $2.1b | 16.20% |
2026 | $2.5b | 20.70% |
2027 | $2.8b | 14.46% |
2028 | $3.2b | 10.74% |
2023 | 12.33% | 61.74% |
---|---|---|
2024 | 18.41% | 49.30% |
2025 | 21.59% | 17.27% |
2026 | 25.62% | 18.67% |
2027 | 28.52% | 11.32% |
2028 | 31.18% | 9.33% |
12 Analysts have issued a Biogen forecast for earnings per share. The average Biogen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $12.17 . This is 9.94% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $14.40 30.08% , the lowest is $10.79 2.53% .
This results in the following potential growth metrics and future valuations:
2023 | $7.97 | 61.81% |
---|---|---|
2024 | $12.17 | 52.70% |
2025 | $14.14 | 16.19% |
2026 | $17.07 | 20.72% |
2027 | $19.54 | 14.47% |
2028 | $21.64 | 10.75% |
Current | 15.70 | 22.94% |
---|---|---|
2024 | 14.28 | 9.04% |
2025 | 12.29 | 13.94% |
2026 | 10.18 | 17.17% |
2027 | 8.89 | 12.67% |
2028 | 8.03 | 9.67% |
Based on analysts' sales estimates for 2024, the Biogen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.14 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.63 .
This results in the following potential growth metrics and future valuations:
Current | 3.28 | 9.89% |
---|---|---|
2024 | 3.14 | 4.17% |
2025 | 3.17 | 0.93% |
2026 | 3.12 | 1.71% |
2027 | 3.03 | 2.75% |
2028 | 2.99 | 1.25% |
Current | 2.74 | 23.49% |
---|---|---|
2024 | 2.63 | 4.19% |
2025 | 2.65 | 0.93% |
2026 | 2.61 | 1.70% |
2027 | 2.54 | 2.75% |
2028 | 2.50 | 1.25% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.